[HTML][HTML] Recent progress in multidisciplinary treatment for patients with esophageal cancer

M Watanabe, R Otake, R Kozuki, T Toihata… - Surgery today, 2020 - Springer
Esophageal cancer is one of the most aggressive gastrointestinal cancers. This review
focuses on eight topics within the multidisciplinary approach for esophageal cancer. As …

Current status and future prospects for esophageal cancer treatment

M Sohda, H Kuwano - Annals of Thoracic and Cardiovascular …, 2017 - jstage.jst.go.jp
The local control effect of esophagectomy with three-field lymph node dissection (3FLD) is
reaching its limit pending technical advancement. Minimally invasive esophagectomy (MIE) …

[HTML][HTML] Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1

Y Kitagawa, T Uno, T Oyama, K Kato, H Kato… - Esophagus, 2019 - Springer
The primary objective of these guidelines is to provide general clinicians with information
that would guide them to make informed choices of the available diagnosis/treatment …

[HTML][HTML] Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1

Y Kitagawa, R Ishihara, H Ishikawa, Y Ito, T Oyama… - Esophagus, 2023 - Springer
The primary objective of these guidelines was to provide general clinicians with information
that would guide them to make informed choices from the available diagnosis/treatment …

Treatment options for esophageal squamous cell carcinoma

M Nakajima, H Kato - Expert opinion on pharmacotherapy, 2013 - Taylor & Francis
Introduction: The treatment for esophageal squamous cell carcinoma (SCC) depends on its
etiology. For mucosal cancer, endoscopic resection is standard; while for locally advanced …

Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the …

M Yamasaki, H Miyata, K Tanaka, O Shiraishi… - Oncology, 2011 - karger.com
Objective: Esophageal squamous cell carcinoma (ESCC) is refractory to current therapeutic
regimens and more effective therapies are imperative. To this end, we conducted a …

[HTML][HTML] Current management of esophageal squamous-cell carcinoma in Japan and other countries

K Higuchi, W Koizumi, S Tanabe, T Sasaki… - Gastrointestinal …, 2009 - ncbi.nlm.nih.gov
The incidence of adenocarcinoma of the distal esophagus or esophagogastric junction has
increased considerably in Western countries during the past 3 decades, whereas the …

Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2)

K Higuchi, S Komori, S Tanabe, C Katada… - International Journal of …, 2014 - Elsevier
Purpose A previous phase 1 study suggested that definitive chemoradiation therapy with
docetaxel, cisplatin, and 5-fluorouracil (DCF-R) is tolerable and active in patients with …

Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared …

KR Haisley, KD Hart, N Nabavizadeh… - Diseases of the …, 2017 - academic.oup.com
Trimodal therapy consisting of neoadjuvant chemoradiation followed by esophagectomy has
become the standard of care in North America for locally advanced esophageal cancer …

Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esopheageal carcinoma

QQ Li, MZ Liu, YH Hu, H Liu, ZY He… - Diseases of the …, 2010 - academic.oup.com
Chemoradiotherapy is a standard treatment for esophageal carcinoma. This study evaluated
the docetaxel-based definitive concomitant chemoradiotherapy in patients with esophageal …